Network building and cross-sectional cooperation.

Technical Director Alf Henrik Andreassen, Haukeland University Hospital:

*Scientific Cooperation at HUH in a Strategic Perspective*

**Abstract:**
The main aim of research at Haukeland University Hospital is to provide effective and high quality health care in a secure way and thus, we conduct and facilitate relevant and high-quality clinical and translational research. We employ about 800 persons engaged in research activities, equivalent to 300 full-time positions, as well as research support staff. In 2014 about 4 % (NOK 405 mill) of our total budget was allocated to research activities according to a national standardized measurement, and we are the second largest university hospital in Norway with regard to research production. In addition, Haukeland University Hospital actively interacts with the University of Bergen bringing together cross-institutional and multi-professional research groups or clusters, making them visible and more powerful in order to answer complex research questions.

Vice Dean for Research, Prof. Eyvind Rødahl, Faculty of Medicine and Dentistry UiB:

*MOF strategy related to network building and cross-sectional cooperation*

**Abstract:**
The University of Bergen recently launched a new strategy for the period 2016 to 2022 prioritizing the areas Climate and energy transition, Marine research and Global societal challenges. By 2022, all faculties at the University are expected to have world-class academic environments and additional disciplines of high international standard. In this talk, I will present some thoughts on how the Faculty of Medicine and Dentistry may contribute to achieve high-quality research and to recruit and train excellent researchers.

Dr. Imke Schneemann, LSN, Kiel and Hamburg, Germany:

*Life Science Nord – The Cluster for Biotech, Pharma and MedTech in Northern Germany*

**Abstract:**
ife Science Nord strengthens the value chain in the region and has established itself as one of the leading life science networks in Europe. In over 500 biotech/pharma and medical technology companies and numerous research institutes, 20,000 highly qualified professionals develop innovative medicines, medical products and services in Hamburg and Schleswig-Holstein. With a complete value chain – from basic and applied research, to clinical tests, to the market-ready end product – the Life Science Nord cluster offers a unique infrastructure: practically oriented researchers and clinical staff cooperate closely with partners in the industry to help innovative products and technologies make the breakthrough.

This engagement for the region is actively supported by Hamburg and Schleswig-Holstein; both states are involved in the Life Science Nord Management GmbH with a 40% share each. This cluster agency coordinates a variety of activities, organises and participates in events, informs about news within the cluster, offers advice and initiates strategic projects for the development of innovative medicine. In addition, about 200 companies and organisations in biomedicine and related industries have organised themselves into the research and industry association Life Science Nord e.V. The association retains a 20% share in the cluster management and pools the interests of its members. In cooperation with the cluster management, the association offers its members additional advantages by means of a partner programme.